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PRLAbstract Objective: Effects of human chorionic gonadotropin combined with clomiphene on
serum E2, FSH, LH and PRL levels in patients with polycystic ovarian syndrome were analyzed.
Methods: 90 patients with polycystic ovarian syndrome treated from January 2015 to March
2016 were randomly and evenly divided into control group and observation group. Patients in
the control group were only treated with clomiphene. On the basis of the treatment in control
group, human chorionic gonadotropin was added in the treatment of observation group. The
changes of E2, FSH, LH, PRL levels were compared between two groups before and after the treat-
ment. Clinical curative effects of patients in the two groups was evaluated. Adverse reactions during
treatment in two groups were observed and recorded. The incidence of adverse reactions was
calculated.
Results: Serum E2, FSH, LH and PRL levels in the two groups decreased signiﬁcantly after
treatment compared with that before treatment. The difference is statistical signiﬁcant
(P< 0.05). After the treatment, E2, FSH, LH and PRL levels in the observation group were lower
than that in the control group and the difference is statistical signiﬁcant (P< 0.05). Total effective
rate was 64.44% in the control group and 93.33% in the observation group. There were statistically
signiﬁcant difference in clinical curative effects in the two groups (P< 0.05). Different degrees of
adverse reactions were found in both groups during treatment, such as nausea, vomiting, anorexia,
liver dysfunction. There were 2 cases of nausea, 2 cases of vomiting, 3 cases of anorexia and 1 case
of liver dysfunction from the 45 patients in control group. The total incidence of adverse reactions
was 17.78% (8/45). There were 1 case of nausea, 1 case of vomiting, 1 case of anorexia and no liver
dysfunction from the 45 patients in observation group. The total incidence of adverse reactions was
Table 1 Comparison of general cli
Materials Cont
Average age (years) 35.46
Average height (cm) 168.2
Average weight (kg) 64.18
Infertility type
Primary infertility 33 (7
Secondary infertility 12 (2
BMI (kg/cm2) 25.02
242 H. Yonggang et al.6.67% (3/45). The total incidence of adverse reactions in the observation group was signiﬁcantly
higher than that in the control group and the difference was not statistically signiﬁcant (P> 0.05).
Conclusion: Combined use of human chorionic gonadotropin can signiﬁcantly reduce serum E2,
FSH, LH and PRL levels, improve clinical curative effects and reduce the incidence of adverse reac-
tions. Human chorionic gonadotropin has high application value on the treatment of polycystic
ovary syndrome.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polycystic ovary syndrome (PCOS) is a common disease of
obstetrics and gynecology. It was mainly caused by anovula-
tion endocrine disorders with clinical manifestations of diver-
sity, including irregular menstruation, infertility, and so on.
According to statistics (Shi and Quan, 2015; Jiang et al.,
2012; Wei et al., 2013), the incidence of polycystic ovary syn-
drome in women of childbearing age was as high as 10%
and it brings seriously negative affect to the healthy and family
life of patients. Drug treatment is the common method of clin-
ical treatment. Analysis on effects of human chorionic gonado-
tropin combined with clomiphene on serum E2, FSH, LH and
PRL levels during the treatment was conducted in this study.
The results are reported as follows.2. Materials and methods
2.1. General information
90 patients with polycystic ovarian syndrome treated from Jan-
uary 2015 to March 2016 were randomly and evenly divided
into control group and observation group. Patient enrollment
criteria: patients clinically diagnosed with polycystic ovary syn-
drome, not using hormonal drugs recently. Exclusion criteria:
patients with liver and kidney dysfunction. This study was
agreed by the patients and approved by our hospital ethical
committee. There were no signiﬁcant difference between the
two groups in general clinical materials, including age, weight,
height, infertility type and BMI, and so on (p> 0.05), and it
was strongly comparable. Data are shown in Table 1.
2.2. Methods
Treatment in the control group: Patients were only treated
with clomiphene. Clomiphene was given orally with the dosenical materials in two groups.
rol group (n= 45) Ob
± 4.12 35.
3 ± 3.42 167
± 4.02 65.
3.33) 30
6.67) 15
± 2.69 25.of 100 mg/d (speciﬁcation: 50 mg  20particle/box, approval
number: national medicine approved number H31021107,
manufacturer: Shanghai Hengshan Pharmaceutical Co.,
Ltd.). The treatment was stopped after 12 d of continuous
medicine taken. It would be extended to three menstrual
cycles, if the patient was not pregnant. Treatment in the obser-
vation group: Clomiphene was combined with human chori-
onic gonadotropin in the treatment. Clomiphene was given
orally with the dose of 100 mg/d. The diameter of follicular
was observed and if it is larger than 18 mm, intramuscular
injection of 100 mg human chorionic gonadotropin was given.
If the patient was not pregnant, the treatment was continued
for three menstrual cycles.
Serum E2, FSH, LH and PRL levels was determined by
immune analyzer after patients in the two groups taking drug
for 3 menstrual cycles.
2.3. Observed indicators
2.3.1. E2, FSH, LH and PRL were chosen as observed indicators
Venous blood was extracted from all patients at 9 am in their
fasting state. After centrifuge separation, the separated serum
was placed in a thermostat of 40 C for storage. Enzyme
linked immunosorbent assay (ELIA) method is applied to
determine the levels of E2, FSH, LH, PRL in serum.
2.3.2. Clinical curative effect criterion (Chen et al., 2013; Li and
Wu, 2015; Chen and Wei, 2015; Wang et al., 2014; Liu, 2014)
According to the menstrual recovery degree, curative effects
could be divided into the following four grades. Healing-
Menstruation returned to normal level during treatment or
one year later, and the patient got pregnant successfully.
Excellent-Menstruation returned to normal level during treat-
ment or one year later, but the patient were failed to get preg-
nant. Improved-The function of ovulation was normal, but the
amount of menstruation is less than normal during treatment
or within one year. Failure-menstrual cycle was seriousservation group (n= 45) t/v2 Value P Value
02 ± 4.57 0.4797 0.6326
.09 ± 4.18 1.4160 0.1603
04 ± 3.17 1.1269 0.2629
(66.67) 3.7479 0.0529
(33.33)
97 ± 2.49 1.7386 0.0856
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(Healing cases + Excellent cases + Improved cases)/total
cases  100.00%.
2.4. Statistical analysis
Data were analyzed using SPSS 18.0. Data were represented as
mean ± standard deviation (x s). Measurement data were
compared using T-test. Count data were compared using chi-
square (v2) test. Grade data were compared using rank sum
test. Result of P< 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Changes of E2, FSH, LH, PRL levels in the two groups
after treatment
Serum E2, FSH, LH and PRL levels in two groups decreased
signiﬁcantly after treatment. The difference is statistical signif-
icant (P< 0.05. The levels of E2, FSH, LH and PRL in obser-
vation group were lower than that in the control group and the
difference was statistical signiﬁcant (P< 0.05). Detail data is
listed in Table 2.
3.2. Evaluation of clinical curative effects in the two groups
The total effective rate was 64.44% in control group and
93.33% in observation group. The difference of clinical cura-
tive effects in the two groups was statistically signiﬁcant
(P< 0.05). Detail data is listed in Table 3.
3.3. Comparison of adverse reactions in the two groups
Different degrees of adverse reactions were found in both
groups during treatment, such as nausea, vomiting, anorexia,
liver dysfunction and ovarian hyper-stimulation. There were
2 cases of nausea, 2 cases of vomiting, 3 cases of anorexia, 1
case of liver dysfunction and 2 cases of ovarian hyper-
stimulation from the 45 patients in control group. The totalTable 2 Changes of E2, FSH, LH and PRL levels in the two group
Indicators Control group (n= 45)
Before treatment After treatm
E2 (pmol/L) 196.23 ± 43.26 176.23 ± 30
FSH (u/L) 7.46 ± 1.48 6.72 ± 1.21
LH (u/L) 13.52 ± 2.14 10.36 ± 2.0
PRL (ng/L) 28.74 ± 11.02 16.12 ± 5.0
Table 3 Evaluation of clinical curative effects in the two groups [n
Groups Healing Excellent
Control group (n= 45) 3 (6.67) 12 (26.67)
Observation group (n= 45) 11 (24.44) 19 (42.22)
v2 Value
P Valueincidence of adverse reactions was 17.78% (8/45). There were
1 case of nausea, 1 case of vomiting, 1 case of anorexia, no
liver dysfunction and no ovarian hyper-stimulation from the
45 patients in observation group. The total incidence of
adverse reactions was 6.67% (3/45). The total incidence of
adverse reactions of the observation group was signiﬁcantly
higher than that of the control group and the difference was
not statistically signiﬁcant (P> 0.05).
4. Discussion
At present, with the accelerating pace of social life, more and
more women suffer from polycystic ovary syndrome, a com-
mon clinical gynecological syndrome (Zhao, 2012; Deng,
2012; Chen et al., 2013; Xu et al., 2013; Zhang et al., 2013;
Guo et al., 2015). It’s a type of metabolic syndrome with clin-
ical features like endocrine disorder, high androgen and
chronic anovulation. The infertility symptom causes various
problems to the patients and their family and affects their hap-
piness severely. The main treatments for polycystic ovary syn-
drome in practice are behavioral therapy, surgery and
medicine, supplemented with proper adjustments to diet struc-
ture. Among them, medical therapy is the most often applied
treatment (Hu et al., 2012; Li and Qiao, 2012; Wang et al.,
2012; Mo and Yang, 2013; Fan et al., 2013). Clomiphene is
a hormone-like biological agent. It can promote the secretion
of gonadotropin from hypothalamus. With estrogen index
improved, resistance to androgen is enhanced and hypothala-
mic releasing of GnRH is increased, then the LH and FSH
levels in serum is raised. However, a number of clinical prac-
tice (Zhu, 2013; Gao et al., 2014; Jiang et al., 2015; Geng
and Xu, 2015; Kuang et al., 2013) show that due to the anti-
estrogen effects of clomiphene, endometrial gets thinner and
sperm pass rate gets lower. After the treatment, the pregnancy
rate is low and the miscarriage rate is high. Human chorionic
gonadotropin is a kind of glycoprotein secreted by placental
trophoblast cells. It can accelerate the secretion of androstene-
dione and progesterone. In addition, it is similar to LH with
respect to property and activity and can improve the ovulation
rate partly (Jin et al., 2014; Liu et al., 2014; Lin et al., 2014).
The combination of clomiphene and human chorionics before and after treatment.
Observation group (n= 45)
ent Before treatment After treatment
.23 197.02 ± 45.16 158.40 ± 32.07
7.39 ± 1.50 5.46 ± 1.09
1 13.46 ± 2.42 8.45 ± 1.75
4 28.19 ± 12.91 14.46 ± 3.72
(%)].
Improved Failure Total eﬀective rate
14 (31.10) 16 (35.56) 29 (64.44)
12 (26.67) 3 (6.67) 42 (93.33)
11.2750
0.0008
244 H. Yonggang et al.gonadotropin can effectively prevent excessive luteinizing and
promote follicle rupture ovulation. This study investigated the
effects of human chorionic gonadotropin combined with clo-
miphene on serum E2, FSH, LH and PRL levels in patients
with polycystic ovarian syndrome based on 90 patients.
The study shows that the serum E2 level in patients treated
with clomiphene alone decreased from 196.23 ± 43.26 pmol/L
before treatment to 176.23 ± 30.23 pmol/L, while the
decreased level was still higher than that in patients treated
with clomiphene combined with human chorionic gonadotro-
pin (158.40 ± 32.07 pmol/L). Serum FSH, LH and PRL levels
in patients treated by both the two methods showed a down-
ward trend after the treatment, while the levels in patients trea-
ted with clomiphene combined with human chorionic
gonadotropin were higher than that in patients treated with
clomiphene alone. It suggested that human chorionic gonado-
tropin can signiﬁcantly reduce serum E2, FSH, LH and PRL
levels. This result is consistent to the reported results (Chen
et al., 2015; Yuan et al., 2015). Out of the 45 patients treated
with clomiphene alone, 29 of them were effectively treated.
The total effective rate was 64.44%. In contrast, 42 patients
were effectively treated, from the total 45 patients treated with
the combinative method. Its total effective rate was 93.33%,
signiﬁcantly higher than that of the former one. Human chori-
onic gonadotropin signiﬁcantly improved the clinical curative
effect. Different degrees of adverse reactions were found in
all patients, such as nausea, vomiting, anorexia and liver dys-
function. There were 8 patients with adverse reactions from 45
patients treated with clomiphene alone and the total incidence
of adverse reactions was 17.78%. There were 3 patients with
adverse reactions from 45 patients treated with clomiphene
combined with human chorionic gonadotropin and the total
incidence of adverse reactions was 17.78%. No liver dysfunc-
tion and ovarian hyper-stimulation were found.
Combined use of human chorionic gonadotropin and clo-
miphene for the treatment of polycystic ovary syndrome can
signiﬁcantly reduce levels of E2, FSH, LH and PRL in serum,
improve clinical curative effect and reduce the incidence of
adverse reactions. Human chorionic gonadotropin has high
application value on the treatment of polycystic ovary
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